Pacira BioSciences (PCRX) Stock News
$PCRX · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Pacira BioSciences (PCRX) in the past 30 days, 1 of it high impact. BORSA’s news read on PCRX is bullish at 75/100, −1 over 24 hours, based on 1 company event over the past 7 days. PCRX last closed at $36.40 on Oct 27, up 0.05% over five sessions and up 43.36% over the past month. Pacira BioSciences’ next earnings report is scheduled for Thursday, Nov 5 before the open.
The wire on $PCRX
newest first · updated · direct subject stories onlyViatris has commenced a tender offer to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash. The offer expires Nov. 16, 2026, and is conditioned on a majority of shares being tendered and antitrust clearance. Pacira's board unanimously recommends that stockholders tender their shares. The transaction is structured under Delaware law Section 251(h), so no stockholder vote is required.
neutral 50 · impact 70The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Pacira BioSciences (PCRX) stock: common questions
Is the news on PCRX bullish or bearish?
BORSA’s news read on PCRX is bullish at 75/100, −1 over 24 hours, based on 1 company event over the past 7 days. It measures the news only: it is separate from price action and is not investment advice.